Eisai global Stock Photos and Images
Eisai Global company logo on a website with blurry stock market developments in the background, seen on a computer screen through a magnifying glass Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/eisai-global-company-logo-on-a-website-with-blurry-stock-market-developments-in-the-background-seen-on-a-computer-screen-through-a-magnifying-glass-image447328363.htmlRF2GYNFTY–Eisai Global company logo on a website with blurry stock market developments in the background, seen on a computer screen through a magnifying glass
Gary Hendler, President and CEO, Eisai EMEA, and President, Eisai Oncology Global Business Unit, visits the ITV Headquarters in London ahead of an announcement, which has now been made by NHS England that the National Cancer Drugs Fund (NCDF) has removed Halaven (eribulin) from the Cancer Drugs Fund (CDF). Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/stock-photo-gary-hendler-president-and-ceo-eisai-emea-and-president-eisai-oncology-107986013.htmlRMG7K579–Gary Hendler, President and CEO, Eisai EMEA, and President, Eisai Oncology Global Business Unit, visits the ITV Headquarters in London ahead of an announcement, which has now been made by NHS England that the National Cancer Drugs Fund (NCDF) has removed Halaven (eribulin) from the Cancer Drugs Fund (CDF).
Los Angeles, California, USA - 25 March 2019: Illustrative Editorial of Eisai website homepage. Eisai logo visible on display screen. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/los-angeles-california-usa-25-march-2019-illustrative-editorial-of-eisai-website-homepage-eisai-logo-visible-on-display-screen-image365963512.htmlRF2C7B25C–Los Angeles, California, USA - 25 March 2019: Illustrative Editorial of Eisai website homepage. Eisai logo visible on display screen.
Gary Hendler, President and CEO, Eisai EMEA, and President, Eisai Oncology Global Business Unit, visits the ITV Headquarters in London ahead of an announcement, which has now been made by NHS England that the National Cancer Drugs Fund (NCDF) has removed Halaven (eribulin) from the Cancer Drugs Fund (CDF). Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/stock-photo-gary-hendler-president-and-ceo-eisai-emea-and-president-eisai-oncology-107986011.htmlRMG7K577–Gary Hendler, President and CEO, Eisai EMEA, and President, Eisai Oncology Global Business Unit, visits the ITV Headquarters in London ahead of an announcement, which has now been made by NHS England that the National Cancer Drugs Fund (NCDF) has removed Halaven (eribulin) from the Cancer Drugs Fund (CDF).
